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INTRODUCTION
Among men, bladder cancer (BCA) is the seventh most com-
mon cancer worldwide and the fourth most common in de-
veloped countries.1 Although cystoscopy and cytology are the 
standard diagnostic tools for BCA, cystoscopy has low sensi-
tivity for high-grade superficial tumors [i.e., carcinoma in situ 
(CIS)] and cytology has poor sensitivity for low-grade tumors.2,3 
Therefore, there is a growing interest in the development of new, 
noninvasive, and accurate methods for the detection of BCA.
Metabolic dysfunction has been implicated in a wide variety 
of human diseases including BCA.4 Recent advances on tech-
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nological and data analysis have enabled the characterization 
of metabolites in biofluids. Metabolomics has been applied in-
creasingly in the field of toxicology and biomarker research,5,6 
in particular for cancer diagnosis.7,8 Growth and division of tu-
mor cells are associated with an increase in the activity of a va-
riety of metabolic pathways. Genes linked to altered cancer 
metabolism contribute to production and secretion of the can-
cer-specific metabolites into biofluids.9 Recent studies report-
ed that metabolites uniquely detected in urine samples from 
patients with BCA, not those in the matched non-cancer con-
trols, could be a useful biomarker for BCA diagnosis and prog-
nosis.4,10-12 Because the bladder serves as a temporary urine res-
ervoir, analysis of urine metabolites could provide potential 
candidates of sensitive and specific biomarkers of BCA.4,10-12 
In our previous study, we used a comprehensive mass spec-
trometry-based metabolomics approach to identify potential 
diagnostic biomarkers of BCA, employing 138 patients with 
BCA and 121 control subjects.13 This previous analysis revealed 
twelve metabolites as potential biomarkers for the detection 
of BCA. They were carnitine, ovalerylcarnitine, glutarylcarni-
tine, octenoylcarnitine, decanoylcarnitine, succinate, pyruvate, 
oxoglutarate, phosphoenolpyruvate, trimethyllysine, melato-
nin, and acetyl-CoA. Carnitine has two key functions: 1) the 
transport of long-chain fatty acids (FAs) into the mitochon-
dria, where they are oxidized to produce energy, and 2) the re-
moval of toxic compounds to prevent their accumulation.14 The 
carnitine-acylcarnitine metabolic pathway involves several en-
zymes, including carnitine palmitoyltransferase type 1 (CPT1) 
and carnitine acetyltransferase (CRAT).15 CPT1, which has sev-
eral isoforms including CPT1A, CPT1B, and CPT1C, is a mito-
chondrial enzyme that plays a role in FA import into mitochon-
dria for β-oxidation. Loss of CPT1 leads to the impaired FA 
oxidation and contributes to the cancer-associated cachexia, 
which is characterized by progressive weight loss resulting from 
a reduction in adipose tissue and skeletal muscle. CRAT catalyz-
es the reversible conversion of acetyl-CoA into acetyl-carnitine.15 
Our earlier urinary metabolomics analysis showed the de-
creased urinary levels of melatonin in BCA patients compared 
to controls.13 Melatonin, a derivative of tryptophan, enters to 
cells via glucose transporters and has a broad range of biologi-
cal functions, including regulation of circadian rhythms and 
detoxification of free radicals.16 Because of its antioxidant prop-
erties, melatonin is considered as a potential agent for the pre-
vention and/or treatment of cancer.16
Due to the limited metabolome databases, there have been 
few studies analyzing the metabolomics databases in the con-
text of the related genes/proteins and biological pathways/
networks. The potential association between specific metabo-
lites and their related tissue gene/protein expression in BCA 
remains unclear. An association between BCA-related metab-
olites and altered biochemical processes fundamental to BCA 
development and progression was proposed in a previous 
study, however, the findings were based on the limited experi-
mental data of phase I/II metabolic enzymes (CYP1A1 and CY-
P1B1).4 In the present study, we assessed the relationship be-
tween the BCA-associated urinary metabolites and gene ex-
pression associated with relevant biological pathways using 
bladder tissues derived from BCA patients and controls. 
MATERIALS AND METHODS
Ethics statement
The study protocol was approved by the Ethics Committee of 
Chungbuk National University, and written informed consent 
was obtained from each subject. The Institutional Review Board 
(IRB) of Chungbuk National University approved the proto-
cols for the collection and analysis of samples (IRB approval 
number GR 2010-12-010). 
Patients and tissue samples
A total of 135 primary BCA samples and 26 control tissue sam-
ples from healthy volunteers were analyzed. 120 of 135 BCA 
samples were overlapped between our previous studies13 and 
the current one. The study included primary tumor samples 
from patients with histologically-verified transitional cell car-
cinoma treated at our institute. All tumors were macrodissect-
ed, typically within 15 minutes of surgical resection. Each BCA 
specimen was verified by pathological analysis of tissue sam-
ples from fresh frozen sections of transurethral resection or 
radical cystectomy specimens. Specimens were frozen in liquid 
nitrogen and stored at -80°C until use. Tumors were staged 
according to the 2002 TNM classification,17 while they were 
graded according to the 1973 World Health Organization grad-
Table 1. Sequences of the Primers Used in This Study
Gene Primer
CPT1A 
S: 5’-CCAAGATCGACCCCTCGTTA-3’
AS: 5’-AGAGCAGCACTTTCAGGGAGTA-3’ 
CPT1B
S: 5’-CATCCAGCTTGCCTGGTTC-3’
AS: 5’-CACAAACACGAGGCAAACAG-3’ 
CPT1C
S: 5’-CATCCAGCTTGCCTGGTTC-3’ 
AS: 5’-CACAAACACGAGGCAAACAG-3’ 
CPT2
S: 5’-TTGAAGACACCATTAGGAGATACC-3’
AS: 5’-CCAGCTGCTCATGCAGTTCTTTT-3’
CRAT
S: 5’-CAGGCCAGATGCTGCATG-3’ 
AS: 5’-TAGTCCAGAAGGGTGACAATAGGG-3’ 
SLC25A20
S: 5’-ACCGAGTTTGCCTGGACA-3’ 
AS: 5’-ACCAAACCCAAAGAAGCACAC-3’
TPH1 
S: 5’-TTTCATCTGCTGAAGTCTCATACC-3’
AS: 5’-AAACCAAGGAACAGTTT-3’
IDO1 
S: 5’-TGCTAAACATCTGCCTGATCTCAT-3’
AS: 5’-CCCCACACATATGCCATGGT-3’ 
CPT, carnitine palmitoyltransferase; CRAT, carnitine O-acetyltransferase; SL-
C25A20, solute carrier family 25 [carnitine/acylcarnitine translocase (CACT)], 
member 20; TPH, tryptophan hydroxylase; IDO, indoleamine 2,3-dioxygenase.
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ing system.18 
Extraction of RNA, synthesis of cDNA, and real-time 
PCR
Extraction of RNA and synthesis of cDNA, and real-time PCR 
were performed, as described previously.19 The primers used 
for gene amplification are shown in Table 1. 
Data and statistical analysis
In this study, two pathways, the carnitine-acylcarnitine meta-
bolic pathway and tryptophan metabolism pathway, were se-
lected for further analysis. The metabolic pathways associated 
with the selected urinary metabolites were identified using 
KEGG pathways (http://www.genome.jp/kegg). The associa-
tion between specific urinary metabolites and their related 
encoding genes was analyzed (Table 2). Differences between 
two groups were analyzed using the Mann-Whitney U test. All 
statistical analyses were performed using SPSS® 21.0 software 
(SPSS Inc., Chicago, IL, USA), with p<0.05 considered statisti-
cally significant.
RESULTS
Baseline characteristics
The mean age of the 135 BCA patients was 65.9±12.62 years. 
Eighty-two (60.7%) patients had non-muscle invasive bladder 
cancer (NMIBC) and 53 (39.3%) had muscle invasive bladder 
cancer (MIBC). The baseline characteristics of the patients are 
shown in Table 3. 
Comparison of gene expression levels between 
NMIBC patients and controls
Our previous urinary metabolomics-based analysis13 showed 
that patients with BCA had the elevated levels of urinary carni-
tine and several acylcarnitines, such as isovalerylcarnitine and 
octenoylcarnitine, and the decreased levels of urinary melato-
nin, glutarylcarnitine, and decanolycarnitine, compared to the 
control group. Bioinformatics analysis suggested that the levels 
of these metabolites may be altered mainly in two metabolic 
pathways, the carnitine-acylcarnitine metabolic pathway and 
the tryptophan metabolism. In order to quantify the expression 
levels of key genes in these two pathways, we performed qRT-
PCR analysis using samples from 135 BCA patients (82 NMIBC 
and 53 MIBC) and 26 controls. Several key enzymes of the car-
nitine-acylcarnitine metabolic pathway or tryptophan path-
way were selected for further validation (Table 2). 
CPT catalyzes the transfer of the acyl group of a FA to carni-
tine to allow its movement from the cytosol to mitochondria for 
oxidation.20 Carnitine-acylcarnitine translocase (CACT, gene 
symbol: SLC25A29) plays a role in transporting both carnitine-
FA complexes and carnitine across the inner mitochondrial 
membrane for beta-oxidation.21 CRAT catalyzes the reaction of 
acetyl-CoA plus carnitine to CoA plus acetylcarnitine.22 Tryp-
tophan hydroxylase (TPH) is involved in the synthesis of the 
neurotransmitters serotonin and melatonin in tryptophan me-
tabolism.23 Indoleamine 2,3-dioxygenase (IDO) is involved in 
the degradation of tryptophan in the tryptophan metabolic pa-
thway.24 In the carnitine-acylcarnitine metabolic pathway, the 
mRNA expression levels of CPT1B and CPT1C, SLC25A20, and 
CRAT, but not CPT1A or CPT2, were significantly lower in 
NIMBC patients than in controls (p<0.05 each) (Table 4, Fig. 1). 
In the tryptophan metabolic pathway, the mRNA expression 
of TPH1 and IDO1 was significantly lower in NIMBC patients 
than in controls (p<0.05). 
Table 2. Selected Urinary Metabolites in Bladder Cancer Patients and Their Related Pathways, Enzymes, and Encoding Genes
Urinary metabolites Up/down Associated pathways Associated enzymes Encoding genes
Carnitine Up Carnitine-acylcarnitine pathway
Carnitine palmitoyltransferase CPT1A, CPT1B, CPT1C, CPT2 
Carnitine/acylcarnitine translocase SLC25A20
Acetylcarnitine - Carnitine O-acetyltransferase CRAT
Melatonin Down Tryptophan metabolism pathway
Tryptophan hydroxylase TPH1
Indoleamine 2,3-dioxygenase IDO1
CPT, carnitine palmitoyltransferase; SLC25A20, solute carrier family 25 [carnitine/acylcarnitine translocase (CACT)], member 20; CRAT, carnitine O-acetyltrans-
ferase; TPH, tryptophan hydroxylase; IDO, indoleamine 2,3-dioxygenase.
Table 3. Baseline Characteristics of Primary Bladder Cancer Patients
Variables Incidence or mean value (%)
Age (yrs) 65.9±12.62
Gender, n (%)
 Male 112 (83.0)
 Female 23 (17.0)
Grade, n (%)
 G1 30 (22.2)
 G2 58 (43.0)
 G3 47 (34.8)
Stage, n (%)
 NMIBC
 Ta 47 (34.8)
 T1 35 (25.9)
 MIBC
 T2 23 (17.0)
 T3 11 (8.1)
 T4 19 (14.1)
NMIBC, non-muscle invasive bladder cancer; MIBC, muscle invasive bladder 
cancer.
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Comparison of gene expression levels between MIBC 
patients and controls 
Among the carnitine-acylcarnitine metabolic pathway-asso-
ciated genes, the expression levels of CPT1B, CPT1C, and CRAT 
were significantly lower in MIBC tissues than those of controls 
(p<0.05) (Table 4, Fig. 1). No significant differences in the ex-
pression of CPT2 and SLC25A20 were observed between MIBC 
patients and controls. CPT1A expression was significantly hi-
gher in MIBC patients than in controls (p=0.008). Among tryp-
tophan metabolism-associated genes, only TPH1, but not IDO1, 
was significantly downregulated in MIBC compared to controls 
(p=0.001). 
Correlation analysis between urinary metabolites and 
tissue mRNA expression in 120 bladder cancer 
patients
Octenoylcarnitine, urinary metabolites, was positively corre-
lated with CPT1A and SLC25A20 (r=0.250, p=0.006 and r= 
0.255, p=0.005, respectively), while decanolylcarnitine was neg-
atively correlated with CPT2 (r=-0.226, p=0.013). Other candi-
date urinary metabolites did not show any significant correla-
tion with tissue RNA expression in BCA patients (Table 5).
Table 4. Comparison of Tissue mRNA Expression Levels in Control vs. NMIBC or MIBC
Gene 
Control NMIBC MIBC
mRNA expression, 
×105 copies/µg,
median (IQR)
mRNA expression, 
×105 copies/µg,
median (IQR)
p value
(control vs.)
mRNA expression, 
×105 copies/µg,
median (IQR)
p value
(control vs.)
CPT1A 133.16 (108.30–153.62) 81.60 (42.30–211.09) 0.233 301.59 (110.27–560.94) 0.008
CPT1B 869.68 (409.04–1530.84) 410.13 (227.18–734.81) 0.001 249.00 (127.34–505.11) <0.001
CPT1C 40.68 (17.27–79.82) 6.46 (2.89–15.06) <0.001 25.14 (6.21–43.09) 0.026
CPT2 707.51 (372.11–867.09) 579.02 (427.90–829.59) 0.272 519.46 (303.93–727.81) 0.052
SLC25A20 332.79 (288.58–562.43) 209.25 (132.17–307.49) <0.001 312.97 (170.26–527.46) 0.095
CRAT 112.16 (71.56–154.01) 44.09 (25.89–90.50) <0.001 67.14 (40.62–108.69) 0.016
TPH1 44.15 (26.64–84.18) 26.33 (13.17–39.24) 0.002 21.58 (11.42–37.15) 0.001
IDO1 54.74 (31.30–228.58) 21.36 (6.39–51.36) <0.001 55.16 (19.71–249.63) 0.314
IQR, interquartile range; CPT, carnitine palmitoyltransferase; SLC25A20, solute carrier family 25 [carnitine/acylcarnitine translocase (CACT)], member 20; CRAT, 
carnitine O-acetyltransferase; TPH, tryptophan hydroxylase; IDO, indoleamine 2,3-dioxygenase.
Fig. 1. Jitter plots showing mRNA levels in normal controls and patients with NMIBC or MIBC. RT-PCR analysis of the mRNA expression of CPT1A, 
CPT1B, CPT1C, CPT2, SLC25A20, CRAT, TPH1, and IDO1 was performed as described in the Materials and Methods section. p values were calculated us-
ing the Mann-Whitney U test. NMIBC, non-muscle invasive bladder cancer; MIBC, muscle invasive bladder cancer; IDO, indoleamine 2,3-dioxygenase; 
CPT, carnitine palmitoyltransferase; CRAT, carnitine O-acetyltransferase; TPH, tryptophan hydroxylase; SLC25A20, solute carrier family 25 [carnitine/acyl-
carnitine translocase (CACT)], member 20.
20
18
16
14
12
10
22
20
18
16
14
12
20
18
16
14
12
10
20
18
16
14
12
10
18
16
14
12
10
8
20
18
16
14
12
10
20
18
16
14
12
10
20
18
16
14
12
10
NMIBC
NMIBC
NMIBC
NMIBC
NMIBC
NMIBC
NMIBC
NMIBC
CPT1A
SLC25A20
CPT1B
CRAT
CPT1C
TPH1
CPT2
IDO1
Cont.
Cont.
Cont.
Cont.
Cont.
Cont.
Cont.
Cont.
p=0.233
p<0.001
p=0.001
p<0.001
p<0.001
p=0.002
p=0.272
p<0.001
p=0.008
p=0.095
p<0.001
p=0.016
p=0.026
p=0.001
p=0.052
p=0.314
MIBC
MIBC
MIBC
MIBC
MIBC
MIBC
MIBC
MIBC
Ge
ne
 e
xp
re
ss
io
n 
(A
.U
.)
Ge
ne
 e
xp
re
ss
io
n 
(A
.U
.)
Ge
ne
 e
xp
re
ss
io
n 
(A
.U
.)
Ge
ne
 e
xp
re
ss
io
n 
(A
.U
.)
Ge
ne
 e
xp
re
ss
io
n 
(A
.U
.)
Ge
ne
 e
xp
re
ss
io
n 
(A
.U
.)
Ge
ne
 e
xp
re
ss
io
n 
(A
.U
.)
Ge
ne
 e
xp
re
ss
io
n 
(A
.U
.)
869
Won Tae Kim, et al.
http://dx.doi.org/10.3349/ymj.2016.57.4.865
DISCUSSION
Our previous study identified twelve urinary metabolites, in-
cluding carnitine, and their derivatives and melatonin, as po-
tential diagnostic biomarkers for BCA.13 The following bioinfor-
matics analysis showed that these metabolites were enriched 
in the carnitine-acylcarnitine or tryptophan metabolic path-
ways. Given that metabolic pathways and associated genes/
proteins/metabolites were altered in BCA, we next tested wh-
ether the expression levels of key genes involved in the carni-
tine-acylcarnitine metabolic pathway and tryptophan metab-
olism are also perturbed in bladder tissues obtained from pa-
tients with BCA. 
A few studies have analyzed carnitine or carnitine metabo-
lism-associated genes in BCA. Huang, et al.11 performed a liq-
uid chromatography (LC) mass spectrometry-based metabo-
lomics analysis and showed that the level of urinary carnitine 
C9:1 was significantly decreased in patients with BCA, partic-
ularly in those with early BCA. However, the contribution and 
regulatory mechanism of the carnitine metabolic pathway to 
BCA remains unclear. 
Increased urinary levels of tryptophan and it’s metabolites 
have been reported in BCA.10,12 Alberice, et al.10 showed that the 
levels of tryptophan and its related metabolite N-acetyltrypto-
phan were significantly increased in the urine of patients with 
early BCA, and Pasikanti, et al.12 showed elevated concentra-
tions of tryptophan metabolites in the urine of BCA patients. 
Despite accumulating evidence supporting the importance of 
tryptophan and its urinary metabolites in bladder carcino-
genesis,25 the role of THP1, a key enzyme in tryptophan metab-
olism that catalyzes the conversion of tryptophan to serotonin 
and the depletion of tryptophan, in BCA has not been investi-
gated to date. Our present data indicate that TPH1 levels are 
significantly decreased in patients with NMIBC and MIBC com-
pared to controls. A tryptophan metabolite, melatonin, was 
also decreased in the urine of patients with BCA. 
Metabolic profiling included high resolution spectroscopy, 
mainly nuclear magnetic resonance, and mass spectro-metry 
with LC or gas-chromatography. Because the final products of 
the metabolism of DNA, RNA, and protein are metabolites, the 
levels of metabolites may be a more accurate reflection of ch-
anges in metabolic activity than the levels of DNA, RNA, and 
Table 5. Correlations between Urinary Metabolites and Tissue mRNA Expression in 120 Bladder Cancer Patients
Carnitine Isovalerylcarnitine Glutarylcarnitine Octenoylcarnitine Decanoylcarnitine Melatonin
r p value r p value r p value r p value r p value r p value
CPT1A -0.133 0.149 0.087 0.342 0.044 0.635 0.250 0.006 -0.172 0.06 - -
CPT1B -0.097 0.298 0.084 0.365 -0.013 0.888 -0.132 0.155 -0.099 0.284 - -
CPT1C -0.062 0.515 0.067 0.481 0.041 0.665 0.025 0.788 -0.105 0.264 - -
CPT2 -0.106 0.249 -0.010 0.913 -0.005 0.955 0.021 0.816 -0.226 0.013 - -
SLC25A20 0.049 0.597 0.088 0.335 -0.027 0.766 0.255 0.005 -0.090 0.324 - -
CRAT 0.102 0.269 0.045 0.626 -0.043 0.645 0.134 0.147 -0.097 0.295 - -
TPH1 - - - - - - - - - - -0.092 0.321
IDO1 - - - - - - - - - - 0.042 0.649
CPT, carnitine palmitoyltransferase; SLC25A20, solute carrier family 25 [carnitine/acylcarnitine translocase (CACT)], member 20; CRAT, carnitine O-acetyltrans-
ferase; TPH, tryptophan hydroxylase; IDO, indoleamine 2,3-dioxygenase.
r=correlation (r).
Fig. 2. Schematic pathway of bladder cancer-associated metabolic signatures in bladder cancer patients. CPT, carnitine palmitoyltransferase; CACT, car-
nitine/acylcarnitine translocase; CRAT, carnitine O-acetyltransferase; TPH, tryptophan hydroxylase; IDO, indoleamine 2,3-dioxygenase.
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protein. Therefore, metabolites could be important diagnostic 
markers because their levels may vary without significant ch-
anges in DNA, RNA, and protein levels, and metabolomics stud-
ies of BCA have been performed using urine, serum, and cancer 
tissues.4,10-12,26,27 Urinary biomarkers for the detection of BCA 
are attractive because of their direct contact to cancer and the 
noninvasive nature of urine collection. Consequently, there has 
been growing interest in urinary metabolomics for BCA detec-
tion. However, validating urinary metabolomics profiles in in-
dependent cohorts or using different methods, and determin-
ing their association with biological properties and specific 
disorders have been challenges that need to be resolved. 
In this study, we proposed the possibility of the association 
between urinary metabolites and tissue mRNA expression in 
BCA in Fig. 2. In the β-oxidation, carnitine and their carnitine 
derivatives are excreted in the urine from BCA tissue, because 
CPT1, CPT2, CACT mRNA expression associated with acyl-car-
nitine and carnitine metabolism were decreased. p53 is well 
known for its tumor suppressive functions and found to mu-
tate in more than 50% MIBC.28 Mutant p53 resulted in TGF-beta 
driven invasion and metastasis in cancer cells.29 In this regard, 
Shariat, et al.30 reported that TGF-beta level in patients with 
MIBC was significantly higher than that in patients with NMIBC 
and normal controls. Interestingly, inhibition of p53 increased 
carnitine palmitoyltransferase 1 activity and p53 regulates mi-
tochondrial respiration.31,32 Therefore, we suggest that the gene 
expression involved in carnitine-acylcarnitine pathway in 
NMIBC might be downregulated compared to MIBC. Similar-
ly, CPT1A gene expression might be upregulated in MIBC 
compared to NMIBC. Additionally, the decreased TPH1 might 
lead to the inhibition of metabolizing the tryptophan pathway 
to target metabolite, melatonin, although the decreased TPH1 
level might be associated with the reduced metabolite such as 
melatonin in tryptophan metabolism. A metabolite in the tryp-
tophan metabolic pathway, acetyl CoA, is the last metabolite 
in the FA metabolism, the glycolysis metabolism and the tryp-
tophan metabolism. In our present study, we found the in-
crease of acetyl-CoA level, which might be caused by the acti-
vated FA and glycolysis metabolism. IDO1 encode the enzyme 
IDO in human. This enzyme is produced by macrophage and 
other immunoregulatory cells.33 Elevation of IDO1 levels in 
bladder tumor cells might be associated with immune escape 
of tumor cells. In particular, in early tumorigenesis periods like 
NMIBC, the human immune systems may downregulate IDO1 
and lead to the protection of cancer cells from immune re-
sponse. 
The present data generated by the use of metabolomics tech-
nologies may broaden our understanding of BCA. However, 
further data interpretation requires a rich integrated database 
of metabolome, transcriptome, and proteome, as well as sys-
tematic bioinformatics approach to confirm the biological func-
tion of metabolite candidates.
In conclusion, we showed that the expressions of genes in-
volved in the carnitine-acylcarnitine and tryptophan pathways 
are associated with alterations in the levels of urinary metabo-
lites in BCA patients. The present results may advance our un-
derstanding of the association between urinary metabolites 
and their related tissue gene expression in BCA.
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